+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Idiopathic Pulmonary Fibrosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type- Product Image
Idiopathic Pulmonary Fibrosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type- Product Image
New

Idiopathic Pulmonary Fibrosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • PDF Icon

    Report

  • 95 Pages
  • March 2025
  • Region: Global
  • Prof Research
  • ID: 5911101
Description Jump to:
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by scarring of lung tissue, leading to reduced oxygen transfer and severe respiratory challenges. With no known cause, IPF predominantly affects individuals aged 70-75, though it is rare in those under 50. Globally, it impacts 13 to 20 per 100,000 people, with approximately 100,000 cases in the U.S. alone and 30,000 to 40,000 new diagnoses annually, according to the National Institutes of Health.

The IPF Drug market focuses on therapies to slow disease progression, manage symptoms, and improve quality of life, featuring key drug types like nintedanib, pirfenidone, and emerging candidates under "Others." The industry is marked by a high unmet clinical need, particularly in markets like China, where only two drugs are approved, driving significant innovation and investment. From 2019 to 2023, China’s IPF treatment market grew from USD 230 million (14.6 billion CNY) to USD 794 million (50.4 billion CNY), with projections to reach USD 1.42 billion (90.3 billion CNY) by 2028, reflecting the global urgency to address this debilitating condition.

Market Size and Growth Forecast

The global Idiopathic Pulmonary Fibrosis Drug market is estimated at USD 4.2 billion to USD 4.8 billion in 2025, with a projected compound annual growth rate (CAGR) of 6% to 8% through 2030, potentially reaching USD 5.8 billion to USD 6.5 billion. This growth is propelled by rising prevalence, aging populations, and advancements in antifibrotic therapies.

Regional Analysis

  • North America: Expected to grow at 5% to 7%, the U.S. leads with high diagnosis rates and robust healthcare infrastructure. Trends emphasize biologics and novel therapies, supported by significant R&D investments.
  • Europe: Forecasted at 4% to 6%, Germany and the UK dominate due to strong pharmaceutical presence. Trends focus on personalized medicine and regulatory support for new drug approvals.
  • Asia Pacific: Projected at 7% to 9%, China drives growth with increasing awareness and healthcare access. Trends highlight rapid market expansion and local drug development to address unmet needs.
  • South Ameica: Anticipated at 3% to 5%, Brazil emerges as a key market. Trends favor affordable generics amid improving diagnostics.
  • Middle East and Africa: Expected at 2% to 4%, South Africa leads with gradual adoption. Trends emphasize cost-effective solutions and partnerships.

Product Type Analysis

  • Nintedanib: Projected at 6% to 8%, this tyrosine kinase inhibitor slows lung function decline, widely adopted for its efficacy. Trends focus on combination therapies and expanded indications.
  • Pirfenidone: Expected at 5% to 7%, it offers anti-fibrotic and anti-inflammatory benefits, dominating in early-stage treatment. Trends lean toward generic versions to enhance accessibility.
  • Others: Forecasted at 8% to 10%, this category includes pipeline drugs like LPA1 antagonists. Trends highlight innovation in precision medicine and novel mechanisms to address severe cases.

Key Market Players

  • AstraZeneca PLC: A UK-based leader, AstraZeneca explores innovative respiratory therapies for IPF.
  • Boehringer Ingelheim: A German giant, it drives the market with nintedanib (Ofev).
  • Bristol Myers Squibb Co.: A U.S. firm, it advances IPF treatment with LPA1 antagonists.
  • Novartis AG: A Swiss innovator, Novartis focuses on novel respiratory solutions.
  • Avalyn Pharma Inc.: A U.S. biotech, Avalyn targets inhaled therapies for IPF.
  • Bellerophon Therapeutics Inc.: A U.S. company, it develops pulmonary disease treatments.
  • Endeavor Biomedicines Inc.: A U.S. entity, Endeavor innovates in fibrotic disease therapies.
  • Horizon Therapeutics: An Irish firm, Horizon explores rare disease treatments, including IPF.
  • Pliant Therapeutics Inc.: A U.S. biotech, Pliant focuses on anti-fibrotic agents.
  • Suzhou Zelgen Biopharmaceuticals Co. Ltd.: A Chinese player, Zelgen boosts local IPF solutions.
  • United Therapeutics Corp: A U.S. firm, it enhances pulmonary care offerings.
  • Vicore Pharma Holding AB: A Swedish company, Vicore targets IPF with unique mechanisms.

Porter’s Five Forces Analysis

  • Threat of New Entrants: Moderate, as high R&D costs and regulatory hurdles deter entry, though unmet needs attract biotechs.
  • Threat of Substitutes: Low-to-moderate, with lung transplantation as an alternative, but drugs remain the primary option.
  • Bargaining Power of Buyers: High, as healthcare providers and insurers negotiate prices amid rising costs.
  • Bargaining Power of Suppliers: Moderate, with API suppliers holding leverage, balanced by global sourcing.
  • Competitive Rivalry: Intense, driven by innovation races and patent expirations among leaders like Boehringer Ingelheim.

Market Opportunities and Challenges

Opportunities

  • Rising Prevalence: Global IPF cases fuel demand for effective therapies, especially in aging populations.
  • Pipeline Innovation: Novel drugs like LPA1 antagonists offer hope for better outcomes, expanding market potential.
  • Emerging Markets: China’s unmet needs and growing healthcare investments create significant growth avenues.
  • Precision Medicine: Advances in targeting fibrotic pathways enhance treatment efficacy, attracting investment.

Challenges

  • Limited Treatment Options: Only two approved drugs in markets like China highlight a gap in comprehensive solutions.
  • High Costs: Expensive therapies strain healthcare budgets, limiting access in developing regions.
  • Regulatory Delays: Stringent approval processes slow the introduction of new drugs, increasing R&D burdens.
  • Disease Complexity: IPF’s unclear etiology complicates drug development, posing risks to efficacy and adoption.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 Introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 Industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Idiopathic Pulmonary Fibrosis Drug Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Idiopathic Pulmonary Fibrosis Drug Market in North America (2020-2030)
8.1 Idiopathic Pulmonary Fibrosis Drug Market Size
8.2 Idiopathic Pulmonary Fibrosis Drug Market by End Use
8.3 Competition by Players/Suppliers
8.4 Idiopathic Pulmonary Fibrosis Drug Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Idiopathic Pulmonary Fibrosis Drug Market in South America (2020-2030)
9.1 Idiopathic Pulmonary Fibrosis Drug Market Size
9.2 Idiopathic Pulmonary Fibrosis Drug Market by End Use
9.3 Competition by Players/Suppliers
9.4 Idiopathic Pulmonary Fibrosis Drug Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Idiopathic Pulmonary Fibrosis Drug Market in Asia & Pacific (2020-2030)
10.1 Idiopathic Pulmonary Fibrosis Drug Market Size
10.2 Idiopathic Pulmonary Fibrosis Drug Market by End Use
10.3 Competition by Players/Suppliers
10.4 Idiopathic Pulmonary Fibrosis Drug Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southeast Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Idiopathic Pulmonary Fibrosis Drug Market in Europe (2020-2030)
11.1 Idiopathic Pulmonary Fibrosis Drug Market Size
11.2 Idiopathic Pulmonary Fibrosis Drug Market by End Use
11.3 Competition by Players/Suppliers
11.4 Idiopathic Pulmonary Fibrosis Drug Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Idiopathic Pulmonary Fibrosis Drug Market in MEA (2020-2030)
12.1 Idiopathic Pulmonary Fibrosis Drug Market Size
12.2 Idiopathic Pulmonary Fibrosis Drug Market by End Use
12.3 Competition by Players/Suppliers
12.4 Idiopathic Pulmonary Fibrosis Drug Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Idiopathic Pulmonary Fibrosis Drug Market (2020-2025)
13.1 Idiopathic Pulmonary Fibrosis Drug Market Size
13.2 Idiopathic Pulmonary Fibrosis Drug Market by End Use
13.3 Competition by Players/Suppliers
13.4 Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Chapter 14 Global Idiopathic Pulmonary Fibrosis Drug Market Forecast (2025-2030)
14.1 Idiopathic Pulmonary Fibrosis Drug Market Size Forecast
14.2 Idiopathic Pulmonary Fibrosis Drug Application Forecast
14.3 Competition by Players/Suppliers
14.4 Idiopathic Pulmonary Fibrosis Drug Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 AstraZeneca PLC
15.1.1 Company Profile
15.1.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.1.3 SWOT Analysis of AstraZeneca PLC
15.1.4 AstraZeneca PLC Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.2 Boehringer Ingelheim
15.2.1 Company Profile
15.2.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.2.3 SWOT Analysis of Boehringer Ingelheim
15.2.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.3 Bristol Myers Squibb Co.
15.3.1 Company Profile
15.3.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.3.3 SWOT Analysis of Bristol Myers Squibb Co.
15.3.4 Bristol Myers Squibb Co. Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.4 Novartis AG
15.4.1 Company Profile
15.4.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.4.3 SWOT Analysis of Novartis AG
15.4.4 Novartis AG Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.5 Avalyn Pharma Inc.
15.5.1 Company Profile
15.5.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.5.3 SWOT Analysis of Avalyn Pharma Inc.
15.5.4 Avalyn Pharma Inc. Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.6 Bellerophon Therapeutics Inc.
15.6.1 Company Profile
15.6.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.6.3 SWOT Analysis of Bellerophon Therapeutics Inc.
15.6.4 Bellerophon Therapeutics Inc. Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.7 Endeavor Biomedicines Inc.
15.7.1 Company Profile
15.7.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.7.3 SWOT Analysis of Endeavor Biomedicines Inc.
15.7.4 Endeavor Biomedicines Inc. Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.8 Horizon Therapeutics Public Limited Company
15.8.1 Company Profile
15.8.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.8.3 SWOT Analysis of Horizon Therapeutics Public Limited Company
15.8.4 Horizon Therapeutics Public Limited Company Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.9 Pliant Therapeutics Inc.
15.9.1 Company Profile
15.9.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.9.3 SWOT Analysis of Pliant Therapeutics Inc.
15.9.4 Pliant Therapeutics Inc. Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.10 Suzhou Zelgen Biopharmaceuticals Co. Ltd.
15.10.1 Company Profile
15.10.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.10.3 SWOT Analysis of Suzhou Zelgen Biopharmaceuticals Co. Ltd.
15.10.4 Suzhou Zelgen Biopharmaceuticals Co. Ltd. Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.11 United Therapeutics Corp
15.11.1 Company Profile
15.11.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.11.3 SWOT Analysis of United Therapeutics Corp
15.11.4 United Therapeutics Corp Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
15.12 Vicore Pharma Holding AB
15.12.1 Company Profile
15.12.2 Main Business and Idiopathic Pulmonary Fibrosis Drug Information
15.12.3 SWOT Analysis of Vicore Pharma Holding AB
15.12.4 Vicore Pharma Holding AB Idiopathic Pulmonary Fibrosis Drug Revenue, Gross Margin and Market Share (2020-2025)
List of Tables and Figures
Table Abbreviation and Acronyms
Table Research Scope of Idiopathic Pulmonary Fibrosis Drug Report
Table Data Sources of Idiopathic Pulmonary Fibrosis Drug Report
Table Major Assumptions of Idiopathic Pulmonary Fibrosis Drug Report
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Idiopathic Pulmonary Fibrosis Drug Picture
Table Idiopathic Pulmonary Fibrosis Drug Classification
Table Idiopathic Pulmonary Fibrosis Drug Applications
Table Drivers of Idiopathic Pulmonary Fibrosis Drug Market
Table Restraints of Idiopathic Pulmonary Fibrosis Drug Market
Table Opportunities of Idiopathic Pulmonary Fibrosis Drug Market
Table Threats of Idiopathic Pulmonary Fibrosis Drug Market
Table COVID-19 Impact For Idiopathic Pulmonary Fibrosis Drug Market
Table Raw Materials Suppliers
Table Different Production Methods of Idiopathic Pulmonary Fibrosis Drug
Table Cost Structure Analysis of Idiopathic Pulmonary Fibrosis Drug
Table Key End Users
Table Latest News of Idiopathic Pulmonary Fibrosis Drug Market
Table Merger and Acquisition
Table Planned/Future Project of Idiopathic Pulmonary Fibrosis Drug Market
Table Policy of Idiopathic Pulmonary Fibrosis Drug Market
Table 2020-2030 North America Idiopathic Pulmonary Fibrosis Drug Market Size
Figure 2020-2030 North America Idiopathic Pulmonary Fibrosis Drug Market Size and CAGR
Table 2020-2030 North America Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2020-2025 North America Idiopathic Pulmonary Fibrosis Drug Key Players Revenue
Table 2020-2025 North America Idiopathic Pulmonary Fibrosis Drug Key Players Market Share
Table 2020-2030 North America Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2020-2030 United States Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Canada Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Mexico Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 South America Idiopathic Pulmonary Fibrosis Drug Market Size
Figure 2020-2030 South America Idiopathic Pulmonary Fibrosis Drug Market Size and CAGR
Table 2020-2030 South America Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2020-2025 South America Idiopathic Pulmonary Fibrosis Drug Key Players Revenue
Table 2020-2025 South America Idiopathic Pulmonary Fibrosis Drug Key Players Market Share
Table 2020-2030 South America Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2020-2030 Brazil Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Argentina Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Chile Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Peru Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Asia & Pacific Idiopathic Pulmonary Fibrosis Drug Market Size
Figure 2020-2030 Asia & Pacific Idiopathic Pulmonary Fibrosis Drug Market Size and CAGR
Table 2020-2030 Asia & Pacific Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2020-2025 Asia & Pacific Idiopathic Pulmonary Fibrosis Drug Key Players Revenue
Table 2020-2025 Asia & Pacific Idiopathic Pulmonary Fibrosis Drug Key Players Market Share
Table 2020-2030 Asia & Pacific Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2020-2030 China Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 India Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Japan Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 South Korea Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Southeast Asia Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Australia Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Europe Idiopathic Pulmonary Fibrosis Drug Market Size
Figure 2020-2030 Europe Idiopathic Pulmonary Fibrosis Drug Market Size and CAGR
Table 2020-2030 Europe Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2020-2025 Europe Idiopathic Pulmonary Fibrosis Drug Key Players Revenue
Table 2020-2025 Europe Idiopathic Pulmonary Fibrosis Drug Key Players Market Share
Table 2020-2030 Europe Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2020-2030 Germany Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 France Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 United Kingdom Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Italy Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Spain Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Belgium Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Netherlands Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Austria Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Poland Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Russia Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 MEA Idiopathic Pulmonary Fibrosis Drug Market Size
Figure 2020-2030 MEA Idiopathic Pulmonary Fibrosis Drug Market Size and CAGR
Table 2020-2030 MEA Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2020-2025 MEA Idiopathic Pulmonary Fibrosis Drug Key Players Revenue
Table 2020-2025 MEA Idiopathic Pulmonary Fibrosis Drug Key Players Market Share
Table 2020-2030 MEA Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2020-2030 Egypt Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Israel Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 South Africa Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Gulf Cooperation Council Countries Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2030 Turkey Idiopathic Pulmonary Fibrosis Drug Market Size
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Region
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Size Share by Region
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Share by Application
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Key Vendors Revenue
Figure 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Size and Growth Rate
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Key Vendors Market Share
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2020-2025 Global Idiopathic Pulmonary Fibrosis Drug Market Share by Type
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Region
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Market Size Share by Region
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Application
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Market Share by Application
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Key Vendors Revenue
Figure 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Market Size and Growth Rate
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Key Vendors Market Share
Table 2025-2030 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Type
Table 2025-2030 Idiopathic Pulmonary Fibrosis Drug Global Market Share by Type

Companies Mentioned

  • AstraZeneca PLC
  • Boehringer Ingelheim
  • Bristol Myers Squibb Co.
  • Novartis AG
  • Avalyn Pharma Inc.
  • Bellerophon Therapeutics Inc.
  • Endeavor Biomedicines Inc.
  • Horizon Therapeutics Public Limited Company
  • Pliant Therapeutics Inc.
  • Suzhou Zelgen Biopharmaceuticals Co. Ltd.
  • United Therapeutics Corp
  • Vicore Pharma Holding AB

Related Topics

Related Reports

Idiopathic Pulmonary Fibrosis Market by Drug Type, Distribution Channel, End-User - Global Forecast 2025-2030 - Product Image

Idiopathic Pulmonary Fibrosis Market by Drug Type, Distribution Channel, End-User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report by Drug Class (Pirfenidone, Nintedanib), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Image

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share & Trends Analysis Report by Drug Class (Pirfenidone, Nintedanib), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-Term Care Facilities, and Others), and Region 2025-2033 - Product Image

Idiopathic Pulmonary Fibrosis Treatment Market Report by Drug Class (MAPK Inhibitors, Tyrosine Inhibitors, Autotaxin Inhibitors), End User (Hospitals, Long-Term Care Facilities, and Others), and Region 2025-2033

  • Report
  • 150 Pages
  • Global
From
Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034 - Product Image

Cough in Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast - 2034

  • Report
  • 72 Pages
  • Global
From
Idiopathic Pulmonary Fibrosis Market Report 2025 - Product Image

Idiopathic Pulmonary Fibrosis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.